Obermatt
See Similar Stocks →

Arrowhead Pharmaceuticals

NSQ:ARWR · US04280A1007
BiotechnologyMedium

360

13
Profit price90
Cash yield1
Price/Sales24
EV / Gross Profit40
Price/Book100
Return on Capital56
Cash Return on Capital24
Return on Equity30
EBIT Margin22
Gross Profitability52
Accruals17
Owner Earnings Margin37
Sales growth25
Profit Growth1
Long-Term EPS Growth38
Reinvestment19
Price momentum98
Debt load14
Refinancing49
Debt Payback1
Liquidity75
Analyst ratings7
Opinion Changes50
Price Target Upside28
Market mood23
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Arrowhead Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Employees668
Websitearrowheadpharma.com
ISINUS04280A1007
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsCardiovascularInflammationCentral Nervous SystemPulmonologyGenetic DisorderHepatologyBiotechnologyElectronicsEnergy StorageNanotechnology

Description

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. There are currently 18 Arrowhead-discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stag…

Analysis

Middle-of-the-road

Arrowhead Pharmaceuticals, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
37
2026

All-time high

78

Mar 2026

All-time low

37

Jun 2026

Average rank

58

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
24
—
—
—
Price/Earnings
85
—
—
—
Price/Book
100
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
94
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Arrowhead Pharmaceuticals with its peers
Avidity Biosciences
NMQ:RNA
28
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Benitec Biopharma
NAQ:BNTC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Alnylam Pharmaceuticals
NSQ:ALNY
79
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Ultragenyx Pharmaceutical
NSQ:RARE
24
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Oric Pharmaceuticals
NSQ:ORIC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →